On April 2, 2025, Alpha Tau Medical Ltd. announced it received FDA approval to start a trial for patients with recurrent glioblastoma, indicating significant progress in their research.
AI Assistant
ALPHA TAU MEDICAL LTD
2025
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.